Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: StudySeptember 21, 2018
A retrospective study suggested that 60 Gy of neoadjuvant concomitant image-guided radiotherapy is safe and effective in locally advanced NSCLC.
In the phase 1/2 ECHO-202/KEYNOTE-037 trial, IDO1 inhibitor epacadostat plus pembrolizumab demonstrated antitumor activity in a NSCLC cohort.
A 10-year updated analysis of a phase 3 trial demonstrated that use of prophylactic cranial irradiation in NSCLC prolonged disease-free survival, but not overall survival.
A phase 3 trial examining niraparib as a maintenance drug for platinum-responsive advanced SCLC is being initiated in China.
Results from Phase 1 expansion cohorts showed that cemiplimab has antitumor activity against relapsed/refractory NSCLC and a safety profile similar to other PD-1 inhibitors.
"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at BaselineSeptember 18, 2018
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
The association between disease progression and PD-1/PD-L1 inhibitors in non-small cell lung cancer is unknown.
Patients with severe complications, such as interstitial lung disease, are often excluded from clinical studies assessing chemotherapy in NSCLC.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Targeted therapies such as EGFR tyrosine kinase inhibitors have improved survival in non-small cell lung cancer, but resistance is a common challenge.
AvaALL was the first phase 3 study to evaluate bevacizumab across multiple lines of treatment beyond progression in patients with non-small cell lung cancer.
Capmatinib has demonstrated preclinical activity in EGFR-mutant and MET-activated non-small cell lung cancer when administered with concurrent EGFR-TKIs.
Researchers Use Artificial Intelligence to Predict Patient Survival from Pathology Images in Lung CancerAugust 28, 2018
Artificial intelligence techniques are being employed to build complex new multivariate prognostic models for patients with lung cancer and other malignancies.
Evidence suggests that S-1 monotherapy may be safe and effective in non-small cell lung cancer.
Apatinib has demonstrated efficacy in the second-line setting for gastrointestinal cancers and may also be effective in non-small cell lung cancer.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.
The decision was based on the ongoing CheckMate-032 phase 1/2 study, in which researchers are investigating nivolumab in patients with advanced or metastatic tumors.
Researchers assessed the outcomes of 73 patients with unresectable advanced non-small-cell lung cancer who were treated with 2 different schedules of IMRT: SMART or H-RT.
There is a lack of data assessing the impact of chronic obstructive pulmonary disorder on mortality in small cell lung cancer.
Even after an adverse event due to treatment with a checkpoint inhibitor, some patients may benefit from re-treatment with drugs from this class.
Asthma inhalation therapies including exercise induced bronchospasm (EIB) and asthma maintenance dosing.
The heterogeneity of resistance may make it difficult for drug developers to create combination therapies that prevent eventual resistance to osimertinib.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Small cell lung cancer, a highly aggressive disease, is diagnosed in 34,000 patients and accounts for nearly 18% of all lung cancer cases in the United States every year.
Previous studies have demonstrated that osimertinib may have the potential to improve outcomes among patients with central nervous system metastases.
Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung CancerAugust 01, 2018
Researchers retrospectively examined 2448 cases of NSCLC submitted to a single diagnostics lab over 3 years.
The IASLC released guidance on the use of biopsies for the detection of EGFR and other tumor mutations in patients with NSCLC.
Though phase 3 studies are ongoing, there is a dearth of evidence that definitively supports the superiority of stereotactic body radiation therapy compared with conventionally fractionated radiation therapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
- Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder